The first stop for professional medicines advice

Medication Safety

56 results

Applied filters

Managing risks associated with oxytocin infusions during labour

24 September 2024Safety strategies can minimise the risk of harms related to oxytocin infusion overdose and delayed therapy.

Using amphotericin B injections

13 September 20243 formulations exist: 1 conventional; 2 liposomal. Conventional and liposomal formulations are not interchangeable; liposomal formulations are interchangeable.

Assessing injectables for enteral administration

13 August 2024Clinical decisions on the use of injectable formulations for enteral administration should be guided by safety and practicality.

Managing the risks associated with patients prescribed clozapine

28 June 2024Healthcare professionals in non-specialist services managing patients prescribed clozapine should implement safe practice principles to prevent potential harms.

Clinical considerations for patients prescribed clozapine

28 June 2024Healthcare professionals in all settings who interact with patients prescribed clozapine should be aware of clinical considerations related to its use.

Managing complexities of medication use across care boundaries

26 June 2024Exploring the risks for patients on complex or specialist medicines moving across care boundaries with a focus on strategies to reduce harms

Medication Safety Update

21 June 2024A resource collating the latest medication safety communications and publications to inform, support and inspire medication safety improvements.

Purchasing for safety

19 June 2024Using principles of purchasing for safety when making purchasing decisions supports the safe clinical use of medicines and can minimise inadvertent harm

Investigating suspected tampering with medicines

11 June 2024A systematic approach should be taken to responding to reports of possible malicious tampering, securing the evidence, and seeking specialist advice and support

Ensuring time critical use of rasburicase

6 March 2024Timely use of rasburicase for treatment of Tumour Lysis Syndrome is essential. Mitigation strategies can minimise harm associated with delayed therapy.